Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: Implications for the timing of a booster dose

European Journal of Pediatrics

Volumn 165, Issue 1, 2006, Pages 14-18

  Trollfors, Birger ^a   Knutsson, Nina ^a   Taranger, John ^a   Mark, Anders ^a   Bergfors, Elisabet ^b   Sundh, Valter ^b   Lagergård, Teresa ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antibodies; Booster dose; Diphtheria; Pertussis; Tetanus

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; DIPHTHERIA TOXIN; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PERTUSSIS ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; HUMAN; IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TETANUS; VACCINATION; VACCINATION REACTION;

ANTIBODIES, BACTERIAL; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; PERTUSSIS VACCINE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SWEDEN;

EID: 29244460078     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-005-1763-3     Document Type: Article

References (20)

1. Ada G (1999) The immunology of vaccination. In: Plotkin SA, Orenstein WA (eds) Vaccines, 4th edn. WB Saunders, Philadelphia, pp 31-46
2. Bergfors E, Trollfors B, Inerot A (2003) Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 22: 64-69
3. Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C (2002) Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 21: 535-541
4. Claesson BA, Trollfors B, Lagergård T, Taranger J, Bryla D, Otterman G, Cramton T, Yang Y, Reimer CB, Robbins JB, Schneerson R (1988) Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18 to 23 month old children. J Pediatr 112: 695-702
5. Danilova E, Shiryayev A, Skogen V, Kristoffersen EK, Sjursen H (2005) Short-term booster effect of diphtheria toxoid in initially long-term protected individuals. Vaccine 23: 1446-450
6. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, Englund JA, Pichichero ME, Deloria MA (1995) Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96: 548-557
7. Granoff DM, Lucas AH (1995) Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann N Y Acad Sci 754: 278-288
8. Lagergård T, Trollfors B, Claesson B, Karlberg J, Taranger J (1992) Determination of neutralizing antibodies and specific immunoglobulin isotype levels in infants after vaccination against diphtheria. Eur J Clin Microbiol Infect Dis 11: 341-345
9. Lugauer S, Heininger U, Cherry JD, Stehr K (2002) Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 161: 142-146
10. Mortimer EA, Wharton M (1998)Diphtheria toxoid. In: Plotkin SA, Orenstein WA (eds) Vaccines, 3rd edn. WB Saunders, Philadelphia, pp 140-157
11. Nilsson L, Faldella G, Jacquet JM, Storsaeter J, Silfverdal SA, Ekholm L (2005) A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. Scand J Infect Dis 37: 221-229
12. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, Bogaerts H, Storsaeter J (2003) Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21: 2015-2021
13. Taranger J, Trollfors B, Lagergård T (1995) Clinical trials of a monocomponent pertussis toxoid vaccine - a technical report. Göteborg, Graphic Systems AB, Goteborg, Sweden
14. Taranger J, Trollfors B, Knutsson N, Sundh V, Lagergard T, Ostergaard E (1999) Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 18: 884-891
15. Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P (2000) Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 18: 2295-2306
16. Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB (1995) A placebo-controlled trial of a pertussis toxoid vaccine. N Engl J Med 333: 1045-1050
17. Trollfors B, Taranger J, Lagergard T, Sundh V (2005) Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid. Pediatr Infect Dis J 24: 85-2486
18. Vitek CR, Brennan MB, Gotway CA, Bragina VY, Govorukina NV, Kravtsova ON, Rhodes PH, Bisgard KM, Strebel PM (1999) Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination. Lancet 353: 355-358
19. Wassilak SGF, Orenstein WA, Sutter RW (1998)Tetanus toxoid. In: Plotkin SA, Orenstein WA (eds) Vaccines, 3rd edn. WB Saunders, Philadelphia, pp 441-474
20. World Health Organization. Vaccines, Immunization and Biologicals. Statistics and Graphics. Available at:http://www.who.int/vaccines-surveillance/ statsAndGraphs.htm